CDC director denies report of ‘banned words’ in budget documents

The Centers for Disease Control and Prevention (CDC) disputed a report in the Washington Post that seven words or phrases, including “fetus,” “transgender” and “science-based,” had been banned from the agency’s budget documents, while other officials said the motivation was to avoid words that could limit chances of obtaining funding from Congress.

The initial story published on Dec. 15 said CDC policy analysts were told not to use the following terms: “vulnerable,” “entitlement,” “diversity,” “transgender,” “fetus,” “evidence-based” and “science-based.” One unnamed CDC analyst said the reaction to the reported ban was “incredulous.”

“It was very much, ‘Are you serious? Are you kidding?’” the analyst said.

Two days later, CDC director Brenda Fitzgerald, MD, disputed the story, saying the agency “remains committed to our public health mission as a science- and evidence-based institution.”

“I want to assure you there are no banned words at CDC,” Fitzgerald tweeted. “We will continue to talk about all our important public health programs.”

HHS spokesman Matt Lloyd was more forceful in his denial of the report, saying in a statement was “a complete mischaracterization of discussions regarding the budget formulation process.”

The New York Times spoke to several former federal officials, who asked not to be named, who suggested this wasn’t really a ban on certain words, but rather suggestions on certain language to avoid in order to win approval for projects from the political appointments at HHS and CDC.

“It’s absurd and Orwellian, it’s stupid and Orwellian, but they are not saying to not use the words in reports or articles or scientific publications or anything else the CDC does,” a former official said. “They’re saying not to use it in your request for money because it will hurt you. It’s not about censoring what CDC can say to the American public. It’s about a budget strategy to get funded.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.